Antihelminthics Market Size

Global Antihelminthics Market Overview

The Antihelminthics Market Size was valued at USD 1.5 Billion in 2022 and is projected to grow from USD 1.6 Billion in 2023 to USD 3.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.92% during the forecast period (2023 - 2032). 

Rising investments in healthcare infrastructure and an increase in the number of infected people worldwide , are the key market drivers enhancing the market growth. 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Antihelminthics Market Trends

• Increasing prevalence of helminth infections is driving the market growth

The market for anthelmintics is expected to expand as helminth illnesses brought on by roundworm, whipworm, hookworm, and other worms become more common. Helminth diseases are spread through the soil by numerous parasitic worm species. 

As of March 2020, the WHO estimates that over 1.5 billion people globally had helminth infections that were spread through the soil. Some of the main disease-causing species of hookworms include Ascaris lumbricoides (roundworms), trichuris trichiura (whipworms), necator americanus, and ancylostoma duodenale. Additionally, it is estimated that S. stercoralis causes harm to 600 million people worldwide. Poor sanitation and hygiene are other factors that contribute to the rise in soil-transmitted helminth infections.

The increasing cost of healthcare contributes to the development of the market for anthelmintics and is a crucial element determining its growth rate. The market dynamics would be further impacted by various government organisations' efforts to strengthen the healthcare infrastructure by boosting funding.

The market for anthelmintic drugs is anticipated to grow as a result of government initiatives and a paradigm shift towards assisting in the management of helminth diseases globally. For instance, the National Deworming Day is a significant effort to eradicate worms in India by the Ministry of Health and Family Welfare. The WHO estimates that 241 million Indian children between the ages of one and 14 are susceptible to parasitic intestinal worms. 

Government suggestions to increase awareness and eradicate helminth infection are therefore anticipated. Additionally, the market for anthelmintics will grow due to the world's ageing population and rise in the number of infected patients. Favourable reimbursement policies will also accelerate the market's expansion.

The development of anthelmintic medications that can cure nematodes using plant-based materials is receiving a lot of attention. Intestinal parasite nematodes are currently a severe problem in both humans and animals. Animals therefore account for a larger revenue share than humans in the market for anthelmintic medications, which is expected to grow at a CAGR of 5% over the course of the forecast period.

Pharmaceutical firms face a hurdle due to anthelmintic medication resistance in both people and animals. As a result, businesses are harnessing components from medicinal plants to develop new anthelmintic medications. 

Companies in the anthelmintic medicine market are stepping up their efforts to explore the biologically active components of medicinal plants that have features similar to those of drugs and have the potential to be effective in treating intestinal parasitic worms in both humans and animals. In this way, medications made from medicinal plants, such as artemether, tiopropium, and galantamine, provide pharmaceutical businesses with a source of income.Thus, driving the Antihelminthics market revenue.

Antihelminthics Market Segment Insights

Antihelminthics Type Insights

The Antihelminthics market segmentation, based on Type, includes benzimidazoles, (albendazole, mebendazole, benzimidazoles, thiabendazole, others), abamectin, salicylanilides (niclosamide, oxyclozanide, rafoxanide, others), praziquantel, and others. Benzimidazoles segment dominated the market in 2022. This is due to the prodrugs prolonged half-lives and the fact that they do not quickly degrade into inactive byproducts. 

It is more effective against immature and arrested larvae and adult nematodes, particularly lungworms, since effective concentrations are sustained for an extended length of time in the gut and plasma.

Antihelminthics Application Insights

The Antihelminthics market segmentation, based on Application, includes schistosomiasis, fasciolasis, filariasis, angiostrongylosis, ascariasis, giardiasis, and others. Schistosomiasis segment dominated the market in 2022. This is because schistosomiasis is becoming more common in many developing nations in tropical and subtropical areas. 

In regions where sanitation and control efforts are insufficient and the bulk of the population lives in poverty, schistosomiasis continues to be a serious health issue with severe socioeconomic implications. 

Schistosomiasis is frequently linked to a number of variables that are highly correlated with the spread of diseases across the nation. Low socioeconomic position, a lack of access to clean water, a lack of basic infrastructure, relatively poor housing quality, and inadequate environmental sanitation are some of these causes.

Antihelminthics End User Insights

The Antihelminthics market segmentation, based on End User, includes hospitals, clinics, and others. Hospitals segment dominated the Antihelminthics market in 2022.The primary drivers of market expansion are the rising popularity of antihelminthic drugs and the initiatives taken by both public and private organisations to build cutting-edge hospitals.

Figure 1: Antihelminthics Market, by End User, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Antihelminthics Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Antihelminthics Market dominated this market in 2022 (45.80%). This is because helminth infections are becoming more common, and rising healthcare costs will further accelerate the market's growth pace in this area. 

The industry's growth rate in this sector will also go up due to the growing focus on developing technology among key market participants. Further, the U.S. Antihelminthics market held the largest market share, and the Canada Antihelminthics market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ANTIHELMINTHICS MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Antihelminthics market accounted for the healthy market share in 2022. The market will be driven by the large elderly population, the availability of funding for research, and government assistance for R&D.Further, the German Antihelminthics market held the largest market share, and the U.K Antihelminthics market was the fastest growing market in the European region.

The Asia Pacific Antihelminthics market is expected to register significant growth from 2023 to 2032. This is a result of the region's rapidly growing senior population. Additionally, the expansion of the healthcare sector's infrastructure and growing government efforts will accelerate the market's expansion in this area. Moreover, China’s Antihelminthics market held the largest market share, and the Indian Antihelminthics market was the fastest growing market in the Asia-Pacific region.

Antihelminthics Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Antihelminthics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Antihelminthics Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Antihelminthics Industry to benefit clients and increase the market sector. In recent years, the Antihelminthics Industry has offered some of the most significant advantages to medicine. 

Major players in the Antihelminthics market, including Abbott, Novartis AG, ZEISS International , Johnson & Johnson Services, Inc., Sanofi, Merck & Co., Inc., GlaxoSmithKline plc., Astellas Pharma Inc., Bayer AG, Mentis Pharma Ltd., Pfizer Inc., Sanofi, ALLERGAN, and AstraZeneca, are attempting to increase market demand by investing in research and development operations.

With a focus on livestock and companion animals, Zoetis Inc. (Zoetis) is an animal healthcare firm that researches, develops, produces, and sells animal health medications, vaccinations, and diagnostic tools. Biodevices, genetic diagnostics, and precision livestock husbandry are used to supplement its goods. The business, among other things, sells vaccines, parasiticides, anti-infective treatments, and medicated feed additives. Through its client supply services (CSS) organisation, it also provides contract manufacturing services to other parties. 

The company has manufacturing sites all around the world, and it sells goods through direct marketing channels and distributors in the Americas, Europe, Africa, Asia, and Australia to veterinarians, livestock producers, as well as people who raise and care for farm and companion animals. The U.S. city of Parsippany, New Jersey, serves as the company's headquarters. Simparica Trio, a medication combination used to prevent heartworm disease, roundworms, rickets, hookworms, and fleas in dogs, was approved by the FDA in February 2020 for Zoetis.

A pharmaceutical firm that develops, produces, promotes, and distributes pharmaceutical drugs is Amneal Pharmaceuticals Inc. (Amneal), originally Amneal Pharmaceuticals LLC. Pharmaceutical products that are offered by it are both generic and specialised. The company also sells products for oncology, inflammation and pain, central nervous system illnesses, endocrinology, and parasite infections, such as Activella, Albenza, Dexedrine, Nizatidine Oral Solution, and Pyridiu. 

Amneal provides goods in a range of dosage forms, including oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids, and other device-driven goods. India, Switzerland, Ireland, and the United Kingdom are all operating hubs for the business. 

The American city of Bridgewater is where Amneal is headquartered. Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. successfully merged in May 2018 to create Amneal Pharmaceuticals, Inc. The generic industry is anticipated to benefit from this deal, making Amneal the fifth-largest generic company in the United States.

Key Companies in the Antihelminthics market include

• Abbott


• Novartis AG


• ZEISS International


• Johnson & Johnson Services, Inc.


• Sanofi


• Merck & Co., Inc.


• GlaxoSmithKline plc.


• Astellas Pharma Inc.


• Bayer AG


• Mentis Pharma Ltd.


• Pfizer Inc.


• Sanofi


• ALLERGAN


• AstraZeneca

Antihelminthics Industry Developments

Sanofi: Concentrated on international outreach initiatives, improving medication accessibility for helminthiasis and other neglected tropical diseases.

In order to enhance treatment adherence in children, Bayer AG has made investments in collaborations to create pediatric formulations of currently available antihelminthics.

April 2019: The WHO prequalified VERMOX (Mebendazole) CHEWABLE, a new medicine from Janssen Pharmaceuticals Inc., for intestinal worms. Following the WHO prequalification, this product is likely to be accessible to young children under the age of one, particularly in nations with a high burden.

September 2018: Albendazole 200 mg tablet's Abbreviated New Drug Application (ANDA) was finally approved, according to Cipla.

Antihelminthics Market Segmentation

Antihelminthics Type Outlook

• 
  

  Benzimidazoles

  
  
  
  
  • Albendazole
  
  
  • Mebendazole
  
  
  • Benzimidazoles
  
  
  • Thiabendazole
  
  
  • Others
  
  
  
  

• 
  

  Abamectin

  
  


• 
  

  Salicylanilides

  
  
  
  
  • Niclosamide
  
  
  • Oxyclozanide
  
  
  • Rafoxanide
  
  
  • Others
  
  
  
  

• 
  

   Praziquantel

  
  


• 
  

  Others

  
  

Antihelminthics Application Outlook

• Schistosomiasis


• Fasciolasis


• Filariasis


• Angiostrongylosis


• Ascariasis


• Giardiasis


• Others

Antihelminthics End User Outlook

• Hospitals


• Clinics


• Others

Antihelminthics Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America